Published in final edited form as:

Anesthesiology. 2013 November ; 119(5): 1006–1008. doi:10.1097/ALN.0b013e3182a8a90c.

Exome Sequencing: One Small Step for Malignant Hyperthermia, One Giant Step for Our Specialty:

Why exome sequencing matters to all of us, not just the experts

Peter Nagele, MD, MSc

Dept of Anesthesiology and Genetics, Washington University School of Medicine, 660 S. Euclid Ave, Box 8054, St. Louis, MO 63110, nagelep@wustl.edu; phone: 314-362-5129; fax: 314-362-1185

One hundred years ago, the traditional world hitherto known to physicists ceased to exist. Within the time span of a generation, the foundations of classical mechanics were shattered by Einstein's theory of relativity and quantum mechanics. A new era and the Golden Age of New Physics began. One hundred years later – today – a comparable revolution is taking place and this time in medicine. Yet, few practicing physicians inside and outside our specialty are aware of this revolution. When future historians will look back at the first decades of the 21st century, they may refer to this time period as the era of genomic medicine. An era where for the first time the full power and information of the human genome became accessible and was harnessed to improve the lives and conditions of everyday patients. Two reports in this issue of *Anesthesiology*^{1,2} represent a milestone for our specialty: for the first time exome sequencing has been used to identify novel mutations for malignant hyperthermia.

What is exome sequencing and why is it relevant for all of us, not just experts?

Exome sequencing is like the little brother of whole genome sequencing.³ For decades a dream of geneticists, sequencing a whole human genome has become a distinct possibility after the Human Genome Project was completed and a first draft released in the year 2000.⁴ At a cost of three billion dollars, with several hundred investigators involved and taking 10 years of work to be completed, the Human Genome Project was without a doubt one of the most ambitious and costly biomedical research projects ever undertaken. While many have questioned if the investment in the Human Genome Project “was worth it” or “has paid off”, all scientific discoveries that jump-started the genomic medicine revolution in the last decade would have been impossible without the Human Genome Project, including exome sequencing. This is for two main reasons: first, the Human Genome Project provided a

Correspondence to: Peter Nagele.

Editorial View for the following articles:

RYR1 and CACNA1S in 4 Malignant Hyperthermia Families by Jerry H. Kim, MD, Gail P. Jarvik, MD, PhD, Brian L. Browning, PhD, Ramakrishnan Rajagopalan, MS, Adam S. Gordon, Mark J. Rieder, PhD, Peggy D. Robertson, PhD, Deborah A. Nickerson, PhD, Nickla A. Fisher, and Philip M. Hopkins, MBBS, MD.

and

Using Exome Data to Identify Patients With Malignant Hyperthermia Susceptibility by Stephen G. Gonsalves; David Ng; Jennifer J. Johnston; Jamie K. Teer; Peter D. Stenson; David N. Cooper; James C. Mullikin; and Leslie G. Biesecker, MD

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

template of the human genome that all subsequently sequenced genomes could be compared to.⁵ Nowadays, geneticists can simply align the millions of little DNA pieces (“shotgun sequencing”) from a human genome on the backbone of a reference genome. Back then, the researchers in the Human Genome Project had to assemble these millions of DNA pieces in the right order first – a painstaking and arduous process (Figure 1). Second, and this is the most dramatic development, the Human Genome Project resulted in a huge technological race towards cheaper and faster sequencing. Outpacing Moore’s law, the law in the semiconductor field that states that the number of transistors on an integrated circuit doubles every 18 months, the cost of sequencing has decreased and the speed of sequencing has increased by several orders of magnitude. In the year 2013, the cost to sequence a whole human genome is around \$ 5,000 (not including analysis) and can be accomplished in less than two weeks. Yet, despite this dramatic reduction in cost and time to sequence a genome, both are still prohibitive for everyday clinical purposes, not even including the time and effort for the non-trivial analysis of the genome data. This is where exome sequencing comes in.

While whole genome sequencing truly sequences the whole human genome with its 3 billion base pairs (typically in 40–50× coverage to remove sequencing errors), exome sequencing represents a smart, efficient and cost-effective approach to identify potentially disease-causing mutations. A mammalian gene is broken up into two parts: exons and introns (Figure 2). Exons are the stretches of DNA that are made (transcribed and translated) into protein (“coding DNA”). The vast majority of disease-causing mutations are located in exons. Introns are not made into protein and typically do not harbor disease causing mutations. All the exons of the human genome combined (“exome”) comprise only a small fraction of the human genome, approximately 1.5%. So instead of sequencing the whole genome (3 billion bases) one could just target and sequence the exome (40 million bases) and still have a reasonably high probability of being able to identify a disease-causing mutation. This smart and efficient approach, originally labeled “targeted exome capture and sequencing” and now simply referred to as exome sequencing, was first used by Jay Shendure’s lab at the University of Washington in Seattle.⁶ An instant landmark achievement, it was first published in 2009 and has been cited more than 500 times since. What is more important than the number of citations, however, is that the novel approach of exome sequencing has spearheaded a revolution in genomic medicine – and this brings us to the questions of relevance.

Why is exome sequencing relevant for more than just experts?

Exome sequencing has become highly relevant and important in less than five years since it was first introduced, because it makes genome sequencing attainable and useful in everyday clinical practice. Today, one can get an exome sequenced for less than \$750 and in just one day, and this has made exome sequencing very attractive for many clinicians (at present mostly pediatricians and oncologists). It should be noted, however, that obtaining the exome data from sequencing requires one day, but not the analysis. The analysis of exome sequencing data is not trivial, requires an experienced bioinformatician and often takes several weeks. Exome sequencing has resulted in some spectacular successes in recent years, particularly in the area of mental retardation and developmental delay⁷, but also by uncovering the genetic basis of schizophrenia⁸ and familial amyotrophic lateral sclerosis⁹, as well as by identifying the causal mutation of several hitherto unidentified rare inherited diseases. One of the most promising applications of exome sequencing is led by Evan Eichler’s group (also at the University of Washington/Howard Hughes Medical Institute) as they have identified several causal gene variants for autism spectrum disorder whose etiology has been enigmatic.^{10,11} Several university hospitals have begun to offer CLIA (Clinical Laboratory Improvement Amendments; a federal laboratory standard)-certified

clinical exome sequencing and it will be only a matter of time, before we will be confronted with our first patient whose exome has been sequenced and whose exome data are accessible on our electronic medical records. It probably will be our colleagues taking care of children with intellectual disabilities and cancer patients who will be confronted with clinical exome data. What are we going to do with them? What is the impact for the practicing anesthesiologist? At present and given the nearly uniform lack of guidelines on how to interpret clinical exome data, the impact is largely negligible. Over the course of the next years, however, as exome data interpretation will become more automated, one of the first areas of relevance for practicing anesthesiologists that should see an integration of exome data will be genotype-based perioperative drug therapy.

While clinical integration of exome results is still in the future, at present we can marvel at the scientific breakthroughs exome sequencing has enabled. The two studies in this issue of *Anesthesiology*,^{1,2} as well as two earlier reports,^{12,13} may represent only an incremental knowledge gain in malignant hyperthermia research. What sets them apart is that by employing exome sequencing they shepherd our specialty into the era of genomic medicine and therefore they truly represent a milestone. What a wonderful coincidence that one of the studies¹ comes from the University of Washington, the very same place where the method of exome sequencing was originally invented.

Acknowledgments

The author is not supported by, nor maintains any financial interest in, any commercial activity that may be associated with the topic of this article.

References

1. Kim JH, Jarvik GP, Browning BL, Rajagopalan R, Gordon AS, Rieder MJ, Robertson PD, Nickerson DA, Fisher NA, Hopkins PM. Exome Sequencing Reveals Novel Rare Variants in RYR1 and CACNA1S in 4 Malignant Hyperthermia Families. *Anesthesiology*. 2013 XXX:XXX-XXX.
2. Gonsalves SG, Ng DN, Johnston JJ, Teer JK, Stenson PD, Cooper DN, Mullikin JC, Biesecker LG. Using Exome Data to Identify Patients With Malignant Hyperthermia Susceptibility. *Anesthesiology*. 2013 XXX:XXX-XXX.
3. Nagele P. Perioperative genomics. *Best Pract Res Clin Anaesthesiol*. 2011; 25:549–555. [PubMed: 22099920]
4. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland J, Kann L, Lehoczky J, LeVine R, McEwan P, McKernan K, Meldrim J, Mesirov JP, Miranda C, Morris W, Naylor J, Raymond C, Rosetti M, Santos R, Sheridan A, Sougnez C, Stange- Thomann N, Stojanovic N, Subramanian A, Wyman D, Rogers J, Sulston J, Ainscough R, Beck S, Bentley D, Burton J, Clee C, Carter N, Coulson A, Deadman R, Deloukas P, Dunham A, Dunham I, Durbin R, French L, Grafham D, Gregory S, Hubbard T, Humphray S, Hunt A, Jones M, Lloyd C, McMurray A, Matthews L, Mercer S, Milne S, Mullikin JC, Mungall A, Plumb R, Ross M, Shownkeen R, Sims S, Waterston RH, Wilson RK, Hillier LW, McPherson JD, Marra MA, Mardis ER, Fulton LA, Chinwalla AT, Pepin KH, Gish WR, Chissole SL, Wendl MC, Delehaunty KD, Miner TL, Delehaunty A, Kramer JB, Cook LL, Fulton RS, Johnson DL, Minx PJ, Clifton SW, Hawkins T, Branscomb E, Predki P, Richardson P, Wenning S, Slezak T, Doggett N, Cheng JF, Olsen A, Lucas S, Elkin C, Uberbacher E, Frazier M, Gibbs RA, Muzny DM, Scherer SE, Bouck JB, Sodergren EJ, Worley KC, Rives CM, Gorrell JH, Metzker ML, Naylor SL, Kucherlapati RS, Nelson DL, Weinstock GM, Sakaki Y, Fujiyama A, Hattori M, Yada T, Toyoda A, Itoh T, Kawagoe C, Watanabe H, Totoki Y, Taylor T, Weissenbach J, Heilig R, Saurin W, Artiguenave F, Brottier P, Bruls T, Pelletier E, Robert C, Wincker P, Smith DR, Doucette- Stamm L, Rubenfield M, Weinstock K, Lee HM, Dubois J, Rosenthal A, Platzer M, Nyakatura G, Taudien S, Rump A, Yang H, Yu J, Wang J, Huang G, Gu J, Hood L, Rowen L, Madan A, Qin S, Davis RW, Federspiel NA, Abola AP, Proctor MJ, Myers RM, Schmutz J, Dickson M, Grimwood J, Cox DR, Olson MV, Kaul R, Shimizu N, Kawasaki K,

Minoshima S, Evans GA, Athanasiou M, Schultz R, Roe BA, Chen F, Pan H, Ramser J, Lehrach H, Reinhardt R, McCombie WR, de la Bastide M, Dedhia N, Blocker H, Hornischer K, Nordsiek G, Agarwala R, Aravind L, Bailey JA, Bateman A, Batzoglu S, Birney E, Bork P, Brown DG, Burge CB, Cerutti L, Chen HC, Church D, Clamp M, Copley RR, Doerks T, Eddy SR, Eichler EE, Furey TS, Galagan J, Gilbert JG, Harmon C, Hayashizaki Y, Haussler D, Hermjakob H, Hokamp K, Jang W, Johnson LS, Jones TA, Kasif S, Kasprzyk A, Kennedy S, Kent WJ, Kitts P, Koonin EV, Korf I, Kulp D, Lancet D, Lowe TM, McLysaght A, Mikkelsen T, Moran JV, Mulder N, Pollara VJ, Ponting CP, Schuler G, Schultz J, Slater G, Smit AF, Stupka E, Szustakowski J, Thierry-Mieg D, Thierry-Mieg J, Wagner L, Wallis J, Wheeler R, Williams A, Wolf YI, Wolfe KH, Yang SP, Yeh RF, Collins F, Guyer MS, Peterson J, Felsenfeld A, Wetterstrand KA, Patrinos A, Morgan MJ, de Jong P, Catanese JJ, Osoegawa K, Shizuya H, Choi S, Chen YJ. Initial sequencing and analysis of the human genome. *Nature*. 2001; 409:860–921. [PubMed: 11237011]

5. Scherer, S. *A Short Guide to the Human Genome*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2008.
6. Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, Lee C, Shaffer T, Wong M, Bhattacharjee A, Eichler EE, Bamshad M, Nickerson DA, Shendure J. Targeted capture and massively parallel sequencing of 12 human exomes. *Nature*. 2009; 461:272–276. [PubMed: 19684571]
7. Vissers LELM, de Ligt J, Gilissen C, Janssen I, Stehouwer M, de Vries P, van Lier B, Arts P, Wieskamp N, del Rosario M, van Bon BWM, Hoischen A, de Vries BBA, Brunner HG, Veltman JA. A de novo paradigm for mental retardation. *Nat Genet*. 2010; 42:1109–1112. [PubMed: 21076407]
8. Xu B, Roos JL, Dexheimer P, Boone B, Plummer B, Levy S, Gogos JA, Karayiorgou M. Exome sequencing supports a de novo mutational paradigm for schizophrenia. *Nat Genet*. 2011; 43:864–868. [PubMed: 21822266]
9. Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, Gibbs JR, Brunetti M, Gronka S, Wu J, Ding J, McCluskey L, Martinez-Lage M, Falcone D, Hernandez DG, Arepalli S, Chong S, Schymick JC, Rothstein J, Landi F, Wang Y-D, Calvo A, Mora G, Sabatelli M, Monsurro MR, Battistini S, Salvi F, Spataro R, Sola P, Borghero G, Galassi G, Scholz SW, Taylor JP, Restagno G, Chiò A, Traynor BJ. Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS. *Neuron*. 2010; 68:857–864. [PubMed: 21145000]
10. O'Roak BJ, Deriziotis P, Lee C, Vives L, Schwartz JJ, Girirajan S, Karakoc E, MacKenzie AP, Ng SB, Baker C, Rieder MJ, Nickerson DA, Bernier R, Fisher SE, Shendure J, Eichler EE. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. *Nat Genet*. 2011; 43:585–589. [PubMed: 21572417]
11. O'Roak BJ, Vives L, Fu W, Egerton JD, Stanaway IB, Phelps IG, Carvill G, Kumar A, Lee C, Ankenman K, Munson J, Hiatt JB, Turner EH, Levy R, O'Day DR, Krumm N, Coe BP, Martin BK, Borenstein E, Nickerson DA, Mefford HC, Doherty D, Akey JM, Bernier R, Eichler EE, Shendure J. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. *Science*. 2012; 338:1619–1622. [PubMed: 23160955]
12. Sambuughin N, Liu X, Bijarnia S, Wallace T, Verma IC, Hamilton S, Muldoon S, Tallon LJ, Wang S. Exome sequencing reveals SCO2 mutations in a family presented with fatal infantile hyperthermia. *J Hum Genet*. 2013; 58:226–228. [PubMed: 23364397]
13. Bohm J, Leshinsky-Silver E, Vassilopoulos S, Le Gras S, Lerman-Sagie T, Ginzberg M, Jost B, Lev D, Laporte J. Samaritan myopathy, an ultimately benign congenital myopathy, is caused by a RYR1 mutation. *Acta Neuropathol*. 2012; 124:575–581. [PubMed: 22752422]

Figure 1.
"I think I found a corner piece!" reprinted with permission from the cartoonist Drew Sheneman.

ALL EXONS in the HUMAN GENOME = EXOME

Figure 2.

Schematic organization of a human (mammalian) gene: exons (black blocks) are the protein coding elements of the gene. Introns (white) are non-coding elements. All exons in the human genome comprise the exome.